Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors

Initially developed as glucose-lowering drugs, sodium-glucose co-transporter type 2 inhibitors (SGLT2i) have demonstrated to be effective agents for the risk reduction of cardiovascular (CV) events in patients with type 2 diabetes mellitus (T2DM). Subsequently, data has emerged showing a significant...

Descripción completa

Detalles Bibliográficos
Autores principales: Margonato, Davide, Galati, Giuseppe, Mazzetti, Simone, Cannistraci, Rosa, Perseghin, Gianluca, Margonato, Alberto, Mortara, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895775/
https://www.ncbi.nlm.nih.gov/pubmed/32901315
http://dx.doi.org/10.1007/s10741-020-10024-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895775/
https://www.ncbi.nlm.nih.gov/pubmed/32901315
http://dx.doi.org/10.1007/s10741-020-10024-2

Ejemplares similares